Premium
Tricyclic and SSRI usage influences the association between BMI and health risk factors
Author(s) -
Serodio K. J.,
Ardern C. I.,
Rotondi M. A.,
Kuk J. L.
Publication year - 2014
Publication title -
clinical obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.64
H-Index - 12
eISSN - 1758-8111
pISSN - 1758-8103
DOI - 10.1111/cob.12067
Subject(s) - medicine , odds ratio , national health and nutrition examination survey , body mass index , blood pressure , confidence interval , insulin resistance , obesity , tricyclic antidepressant , diabetes mellitus , risk factor , endocrinology , antidepressant , environmental health , population , hippocampus
Summary To determine if selective‐serotonin reuptake inhibitors ( SSRIs ) and tricyclic antidepressants ( TCAs ) influence the association between obesity and cardiovascular disease risk, participants from the T hird N ational H ealth and N utrition E xamination S urvey ( NHANES III ; 1988–1992) and continuous NHANES (1999–2009, n = 18 274) were used. For a given body mass index ( BMI ), individuals taking SSRIs ( n = 219) tended to have significantly better health risk profiles with lower systolic blood pressure ( P = 0.002) and higher high‐density lipoprotein ( P = 0.003) compared with non‐users. Conversely, those who used TCAs ( n = 116) had significantly worse health risk profiles with higher diastolic blood pressure ( P ≤ 0.0001) and triglycerides ( P = 0.023) as compared with non‐users for a given BMI . Insulin resistance ( HOMA‐IR ) was higher in TCA users and those with larger BMIs , whereby the differences in insulin resistance between TCA users and non‐users was greater with higher BMIs (interaction effect: P = 0.013). Furthermore, individuals taking SSRIs were less likely to have cardiovascular disease than non‐users (odds ratio, 95% confidence interval = 0.50, 0.33–0.75) for a given BMI , with no differences by TCA use (odds ratio = 0.74, 0.44–1.24). SSRI and TCA use may alter how body weight relates with cardiovascular risk. When prescribing antidepressant medications, it may be necessary to monitor and consider body weight and cardiovascular risk profile of individual patients.